US2018250381A1PendingUtilityA1

Soluble needle arrays for delivery of influenza vaccines

70
Assignee: SEQIRUS UK LTDPriority: Aug 20, 2010Filed: Oct 12, 2017Published: Sep 6, 2018
Est. expiryAug 20, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Derek O'HaganManmohan SinghSung-Yun Kwon
A61K 39/12A61B 17/205G01N 33/68A61K 2039/5252G01N 2333/11A61B 2017/00004A61M 2037/0046A61K 2039/54C12N 2760/16134C12N 2760/16234A61K 9/146C12N 2760/16211A61K 2039/70C12N 2760/16111A61K 39/145A61M 37/0015A61M 2202/30A61M 2037/0023
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

Claims

exact text as granted — not AI-modified
1 - 2 . (canceled) 
     
     
         3 . An aqueous liquid or solid material comprising: (i) a biosoluble and biodegradable matrix material and (ii) an influenza vaccine selected from the group consisting of a purified influenza virus surface antigen vaccine, an influenza vaccine prepared from viruses grown in cell culture, a monovalent influenza vaccine, a bivalent vaccine, a tetravalent or >4-valent vaccine, a mercury free vaccine, and a gelatin-free vaccine. 
     
     
         4 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a purified influenza virus surface antigen vaccine. 
     
     
         5 - 6 . (canceled) 
     
     
         7 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is an influenza vaccine prepared from viruses grown in cell culture. 
     
     
         8 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a monovalent influenza vaccine. 
     
     
         9 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a bivalent influenza vaccine. 
     
     
         10 . aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a tetravalent influenza vaccine. 
     
     
         11 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a >4-valent influenza vaccine. 
     
     
         12 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a mercury-free influenza vaccine. 
     
     
         13 . The aqueous liquid or solid material of  claim 3 , wherein the influenza vaccine is a gelatin-free influenza vaccine. 
     
     
         14 . The aqueous liquid or solid material of  claim 3 , wherein the matrix material comprises one or more carbohydrates. 
     
     
         15 . The aqueous liquid or solid material of  claim 14 , wherein the matrix material comprises a cellulose and/or a dextrin and/or a disaccharide. 
     
     
         16 - 19 . (canceled) 
     
     
         20 . The aqueous liquid or solid material of  claim 3 , comprising between 0.5-50 μg of detergent per pg of hemagglutinin. 
     
     
         21 . aqueous liquid or solid material of  claim 3 , containing 1-15 μg of hemagglutinin per influenza virus strain. 
     
     
         22 - 25 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.